Abstract
Background: The COVID-19 epidemic raises important questions about the efficacy of vaccines for people treated with ocrelizumab, an anti-CD20 therapy. Ocrelizumab has been shown to reduce the humoral response to SARS-CoV-2 infection and vaccination, but the T-cell response to vaccination has not been fully characterized. We sought to provide data regarding B and T-cell mediated responses to SARS-CoV-2 vaccination in ocrelizumab-treated patients, and to determine what variables correlate with vaccine immunogenicity. We hypothesized that patients without a humoral response to SARS-CoV-2 vaccination would still have intact T-cell responses.
Methods: We conducted a prospective, observational, single center cohort study of patients with MS treated with either ocrelizumab or natalizumab as a comparator between March 2, 2021, and July 1, 2021. Eligible patients were age 18 to 55 and had no known prior infection with, or vaccination against, SARS-CoV-2. Patients with prior use of immunosuppressive or chemotherapeutic agents, or treatment with any anti-CD20 therapy other than ocrelizumab within 12 months of enrollment, were excluded. The Roche Elecsys anti-SARS-CoV-2 S immunoassay was performed prior to and 3-4 weeks post vaccination to evaluate the antibody response to SARS-CoV-2 spike IgG. The Adaptive Biotechnologies T-Detect COVID Test was performed to evaluate the adaptive T-cell immune response to SARS-CoV-2 in OCR-treated patients with no detectable antibodies. Data were analyzed using descriptive statistics, Fisher’s exact test, and Wilcoxon rank sum.
Results: Forty-eight patients were enrolled in the study, 69% treated with ocrelizumab and 31% treated with natalizumab. Eighteen percent of ocrelizumab and 100% of natalizumab patients had a positive antibody response. In ocrelizumab-treated patients, there was no correlation between age, sex, BMI, total number of infusions, immunoglobulin G, CD19, or absolute lymphocyte count and antibody response. There was a trend suggesting that a longer interval between the last infusion and vaccination increased the likelihood of producing antibodies (P = 0.062). All ocrelizumab patients with negative antibody responses had positive T-cell responses.
Conclusions: Treatment with ocrelizumab substantially impaired the humoral response to SAR-CoV-2 vaccination but did not impair T-cell responses. Further research is needed to determine if the T-cell response to SARS-CoV-2 vaccination is sufficient to prevent infection or reduce severity of COVID in patients who did not produce antibodies.
Keywords: COVID-19; Coronavirus vaccine; Immunogenicity; Multiple sclerosis; Natalizumab; Ocrelizumab; SARS-CoV-2.
【저자키워드】 COVID-19, SARS-CoV-2, immunogenicity, multiple sclerosis, Natalizumab, coronavirus vaccine, Ocrelizumab, 【초록키워드】 Treatment, antibodies, SARS-CoV-2, IgG, Efficacy, Vaccine, coronavirus, immune response, vaccination, immunogenicity, SAR-CoV-2, adaptive, multiple sclerosis, antibody, SARS-COV-2 infection, severity, Antibody Response, T-cell Response, Infection, Test, Sex, anti-CD20 therapy, cohort study, COVID, lymphocyte, immunoassay, Natalizumab, Immunoglobulin G, Humoral response, Immunoglobulin, response, Research, Patient, age, coronavirus vaccine, T-cell, BMI, Roche, patients, T-cell responses, SARS-CoV-2 vaccination, Ocrelizumab, SARS-CoV-2 spike, Absolute lymphocyte count, COVID-19 epidemic, immunosuppressive, vaccine immunogenicity, humoral, CD19, Enrollment, chemotherapeutic agents, Eligible patients, Descriptive statistics, comparator, single center, no correlation, positive, Fisher's exact test, Multiple, post vaccination, Fisher, variable, positive antibody response, Wilcoxon rank sum, Anti-SARS-CoV-2 S, Prevent, likelihood, raise, enrolled, shown, analyzed, evaluate, detectable, conducted, was performed, characterized, treated, determine, question, reduce, producing, had no, impair, the antibody response, Adaptive Biotechnology, B and T-cell, did not produce, Elecsy, negative antibody response, were excluded, 【제목키워드】 patients treated,